| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 17 | 2022 | 595 | 4.120 |
Why?
|
| Immunotherapy, Adoptive | 11 | 2018 | 131 | 3.170 |
Why?
|
| Receptors, Antigen, T-Cell | 12 | 2019 | 135 | 2.570 |
Why?
|
| Immunotherapy | 7 | 2022 | 212 | 2.490 |
Why?
|
| Melanoma | 17 | 2022 | 335 | 2.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 18 | 2022 | 265 | 2.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 10 | 2016 | 79 | 2.050 |
Why?
|
| Neoplasms | 12 | 2022 | 1660 | 1.810 |
Why?
|
| T-Lymphocytes, Regulatory | 11 | 2022 | 199 | 1.740 |
Why?
|
| Vitiligo | 6 | 2020 | 12 | 1.670 |
Why?
|
| Lymphocyte Activation | 18 | 2018 | 397 | 1.530 |
Why?
|
| ADP-ribosyl Cyclase 1 | 3 | 2020 | 24 | 1.530 |
Why?
|
| NAD | 4 | 2020 | 73 | 1.500 |
Why?
|
| Melanoma, Experimental | 4 | 2020 | 95 | 1.420 |
Why?
|
| Neoplasms, Experimental | 4 | 2018 | 118 | 1.350 |
Why?
|
| Dendritic Cells | 9 | 2018 | 201 | 1.260 |
Why?
|
| Sirtuin 1 | 4 | 2020 | 47 | 1.210 |
Why?
|
| Mice, Inbred C57BL | 25 | 2021 | 2790 | 1.190 |
Why?
|
| Adoptive Transfer | 7 | 2019 | 100 | 1.090 |
Why?
|
| eIF-2 Kinase | 3 | 2022 | 49 | 1.060 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2022 | 126 | 1.050 |
Why?
|
| Neoplasm Proteins | 9 | 2009 | 307 | 1.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 756 | 1.000 |
Why?
|
| Epitopes, T-Lymphocyte | 6 | 2009 | 38 | 0.960 |
Why?
|
| Animals | 49 | 2022 | 20877 | 0.940 |
Why?
|
| Mice | 35 | 2022 | 8472 | 0.940 |
Why?
|
| Epitopes | 8 | 2014 | 146 | 0.920 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 3 | 2018 | 87 | 0.890 |
Why?
|
| Cellular Reprogramming | 2 | 2019 | 22 | 0.880 |
Why?
|
| Sphingosine | 3 | 2021 | 315 | 0.870 |
Why?
|
| Thioredoxins | 2 | 2019 | 26 | 0.860 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 58 | 0.830 |
Why?
|
| Interferon-gamma | 6 | 2016 | 241 | 0.820 |
Why?
|
| Graft vs Host Disease | 6 | 2022 | 163 | 0.810 |
Why?
|
| Oxidative Stress | 5 | 2019 | 718 | 0.800 |
Why?
|
| Apoptosis | 7 | 2022 | 1640 | 0.780 |
Why?
|
| Immunity, Innate | 2 | 2012 | 156 | 0.770 |
Why?
|
| Cancer Vaccines | 4 | 2017 | 61 | 0.750 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 304 | 0.740 |
Why?
|
| Mice, Transgenic | 11 | 2021 | 1032 | 0.730 |
Why?
|
| Lysophospholipids | 2 | 2019 | 209 | 0.730 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2019 | 200 | 0.720 |
Why?
|
| Autoimmunity | 5 | 2020 | 118 | 0.690 |
Why?
|
| Humans | 65 | 2022 | 68525 | 0.690 |
Why?
|
| Retinal Ganglion Cells | 3 | 2020 | 72 | 0.690 |
Why?
|
| PPAR gamma | 1 | 2019 | 95 | 0.670 |
Why?
|
| Interleukin-15 | 5 | 2018 | 66 | 0.670 |
Why?
|
| Thiazolidines | 1 | 2018 | 23 | 0.670 |
Why?
|
| Mice, Knockout | 12 | 2020 | 1692 | 0.660 |
Why?
|
| Cell Line, Tumor | 12 | 2019 | 1849 | 0.640 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 86 | 0.630 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 184 | 0.630 |
Why?
|
| Polylysine | 1 | 2017 | 13 | 0.610 |
Why?
|
| Skin Neoplasms | 4 | 2020 | 375 | 0.610 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2017 | 7 | 0.610 |
Why?
|
| Antioxidants | 3 | 2019 | 304 | 0.600 |
Why?
|
| Antigen Presentation | 5 | 2006 | 76 | 0.600 |
Why?
|
| Poly I-C | 1 | 2017 | 20 | 0.600 |
Why?
|
| Vaccination | 3 | 2017 | 182 | 0.590 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 370 | 0.590 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2018 | 231 | 0.570 |
Why?
|
| Anthracenes | 3 | 2006 | 26 | 0.570 |
Why?
|
| Monophenol Monooxygenase | 3 | 2015 | 8 | 0.550 |
Why?
|
| Mitochondria | 6 | 2021 | 643 | 0.550 |
Why?
|
| Interleukin-2 | 4 | 2018 | 133 | 0.530 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2006 | 140 | 0.530 |
Why?
|
| 5'-Nucleotidase | 1 | 2014 | 13 | 0.510 |
Why?
|
| Antigens, Neoplasm | 6 | 2017 | 132 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 331 | 0.500 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 88 | 0.490 |
Why?
|
| Sulfhydryl Compounds | 1 | 2014 | 73 | 0.490 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2022 | 245 | 0.480 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 332 | 0.470 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 756 | 0.460 |
Why?
|
| Skin | 5 | 2020 | 451 | 0.450 |
Why?
|
| Chemokine CCL22 | 3 | 2017 | 6 | 0.440 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 37 | 0.420 |
Why?
|
| Lymphocytes | 2 | 2012 | 228 | 0.420 |
Why?
|
| Leukemia | 2 | 2022 | 117 | 0.410 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 211 | 0.400 |
Why?
|
| Biological Products | 1 | 2012 | 78 | 0.390 |
Why?
|
| Viral Matrix Proteins | 2 | 2009 | 10 | 0.390 |
Why?
|
| Cells, Cultured | 12 | 2020 | 2673 | 0.380 |
Why?
|
| Carcinoma | 1 | 2012 | 215 | 0.370 |
Why?
|
| Isoantigens | 4 | 2019 | 26 | 0.370 |
Why?
|
| Hypopigmentation | 3 | 2015 | 12 | 0.370 |
Why?
|
| Flow Cytometry | 6 | 2016 | 489 | 0.370 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2022 | 99 | 0.370 |
Why?
|
| Reactive Oxygen Species | 4 | 2019 | 499 | 0.360 |
Why?
|
| Histone Deacetylases | 2 | 2020 | 99 | 0.360 |
Why?
|
| Superoxides | 1 | 2009 | 70 | 0.350 |
Why?
|
| Signal Transduction | 8 | 2021 | 2688 | 0.340 |
Why?
|
| Cell Proliferation | 11 | 2019 | 1173 | 0.330 |
Why?
|
| L-Selectin | 2 | 2019 | 28 | 0.320 |
Why?
|
| Interleukin-12 | 3 | 2022 | 75 | 0.310 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 2550 | 0.310 |
Why?
|
| Membrane Proteins | 3 | 2022 | 617 | 0.300 |
Why?
|
| Interleukin-10 | 3 | 2020 | 144 | 0.300 |
Why?
|
| Melanocytes | 3 | 2020 | 23 | 0.300 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2022 | 226 | 0.280 |
Why?
|
| Mitochondrial Dynamics | 2 | 2022 | 17 | 0.260 |
Why?
|
| Th17 Cells | 2 | 2017 | 116 | 0.260 |
Why?
|
| Phenotype | 4 | 2019 | 946 | 0.250 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2019 | 91 | 0.250 |
Why?
|
| Bone Marrow Transplantation | 3 | 2019 | 149 | 0.240 |
Why?
|
| Epidermis | 2 | 2014 | 42 | 0.240 |
Why?
|
| Receptors, Opioid, delta | 2 | 2020 | 37 | 0.230 |
Why?
|
| HLA-A2 Antigen | 4 | 2012 | 18 | 0.230 |
Why?
|
| Th1 Cells | 2 | 2017 | 101 | 0.230 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2008 | 66 | 0.230 |
Why?
|
| Uveitis | 1 | 2022 | 13 | 0.220 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2022 | 33 | 0.220 |
Why?
|
| Antigens | 2 | 2020 | 90 | 0.220 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2022 | 3 | 0.220 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2022 | 18 | 0.220 |
Why?
|
| Transduction, Genetic | 3 | 2015 | 81 | 0.220 |
Why?
|
| Inflammasomes | 1 | 2022 | 39 | 0.220 |
Why?
|
| Neovascularization, Pathologic | 2 | 2022 | 183 | 0.210 |
Why?
|
| Macrophages | 1 | 2006 | 647 | 0.210 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 37 | 0.210 |
Why?
|
| Cell Death | 3 | 2009 | 329 | 0.210 |
Why?
|
| Female | 16 | 2021 | 38015 | 0.210 |
Why?
|
| Eosinophils | 1 | 2022 | 60 | 0.210 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 65 | 0.210 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2021 | 8 | 0.200 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1034 | 0.200 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 102 | 0.200 |
Why?
|
| Osteoblasts | 2 | 2021 | 99 | 0.200 |
Why?
|
| Immunologic Factors | 1 | 2022 | 87 | 0.200 |
Why?
|
| Receptors, Lysosphingolipid | 2 | 2019 | 63 | 0.200 |
Why?
|
| Carrier State | 1 | 2021 | 39 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 507 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 5 | 2021 | 532 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 332 | 0.190 |
Why?
|
| Ceramides | 2 | 2022 | 578 | 0.190 |
Why?
|
| Osteogenesis | 2 | 2021 | 152 | 0.190 |
Why?
|
| Acid Ceramidase | 1 | 2021 | 85 | 0.190 |
Why?
|
| Bortezomib | 1 | 2020 | 45 | 0.190 |
Why?
|
| Glaucoma | 1 | 2020 | 50 | 0.190 |
Why?
|
| Optic Disk | 1 | 2020 | 37 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 13 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2021 | 268 | 0.190 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 186 | 0.190 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2020 | 20 | 0.190 |
Why?
|
| Autophagy | 1 | 2022 | 207 | 0.180 |
Why?
|
| Heterografts | 2 | 2019 | 70 | 0.180 |
Why?
|
| Blotting, Western | 3 | 2020 | 954 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 110 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 209 | 0.180 |
Why?
|
| Genetic Engineering | 1 | 2019 | 41 | 0.180 |
Why?
|
| Glutathione | 2 | 2020 | 343 | 0.180 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 54 | 0.180 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 23 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 92 | 0.180 |
Why?
|
| Male | 13 | 2021 | 37281 | 0.180 |
Why?
|
| Immune Tolerance | 2 | 2014 | 114 | 0.180 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2019 | 16 | 0.180 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2019 | 18 | 0.180 |
Why?
|
| Coculture Techniques | 3 | 2018 | 147 | 0.170 |
Why?
|
| Benzamides | 1 | 2020 | 156 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 41 | 0.170 |
Why?
|
| T-Box Domain Proteins | 1 | 2019 | 29 | 0.170 |
Why?
|
| Peptides | 4 | 2017 | 455 | 0.170 |
Why?
|
| Transcription Factor CHOP | 1 | 2019 | 28 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 163 | 0.170 |
Why?
|
| Piperazines | 1 | 2020 | 206 | 0.170 |
Why?
|
| Endothelial Cells | 2 | 2021 | 384 | 0.170 |
Why?
|
| Histones | 1 | 2019 | 111 | 0.170 |
Why?
|
| Transplantation Immunology | 1 | 2018 | 11 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 151 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 411 | 0.160 |
Why?
|
| Dental Pulp | 1 | 2018 | 10 | 0.160 |
Why?
|
| Heart Transplantation | 1 | 2021 | 328 | 0.160 |
Why?
|
| Periodontal Ligament | 1 | 2018 | 16 | 0.160 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2018 | 41 | 0.160 |
Why?
|
| Sphingolipids | 1 | 2021 | 337 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 481 | 0.160 |
Why?
|
| Health | 2 | 2020 | 26 | 0.160 |
Why?
|
| Pigmentation | 2 | 2015 | 12 | 0.160 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2017 | 20 | 0.160 |
Why?
|
| Astrocytes | 1 | 2020 | 270 | 0.160 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2018 | 53 | 0.160 |
Why?
|
| Antibodies | 1 | 2018 | 241 | 0.160 |
Why?
|
| Glutamine | 1 | 2017 | 45 | 0.150 |
Why?
|
| Immunotherapy, Active | 1 | 2017 | 6 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 1 | 2018 | 65 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 53 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2020 | 597 | 0.150 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 21 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 267 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 2 | 2022 | 247 | 0.150 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 742 | 0.150 |
Why?
|
| Pancreatitis, Chronic | 1 | 2019 | 168 | 0.150 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 145 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2018 | 110 | 0.150 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 329 | 0.140 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2016 | 30 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2018 | 222 | 0.140 |
Why?
|
| Biomarkers | 4 | 2022 | 1593 | 0.140 |
Why?
|
| Autoimmune Diseases | 2 | 2020 | 186 | 0.140 |
Why?
|
| Oxidation-Reduction | 2 | 2020 | 567 | 0.140 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2018 | 93 | 0.140 |
Why?
|
| Necrosis | 1 | 2016 | 239 | 0.140 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2015 | 6 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 32 | 0.140 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2015 | 9 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 284 | 0.140 |
Why?
|
| Moloney murine leukemia virus | 1 | 2015 | 13 | 0.130 |
Why?
|
| Interleukin-7 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Transplantation, Homologous | 3 | 2022 | 242 | 0.130 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 320 | 0.130 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2015 | 9 | 0.130 |
Why?
|
| Aging | 1 | 2021 | 911 | 0.130 |
Why?
|
| Apyrase | 1 | 2014 | 10 | 0.130 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 27 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2014 | 35 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 78 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2014 | 75 | 0.120 |
Why?
|
| Inflammation | 3 | 2022 | 1030 | 0.120 |
Why?
|
| Receptors, CCR5 | 1 | 2013 | 7 | 0.120 |
Why?
|
| Immunity | 1 | 2014 | 67 | 0.120 |
Why?
|
| Receptors, CXCR3 | 1 | 2013 | 16 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 1174 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2014 | 230 | 0.120 |
Why?
|
| Acetylcysteine | 1 | 2016 | 296 | 0.120 |
Why?
|
| Disease Progression | 2 | 2013 | 1037 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2013 | 45 | 0.110 |
Why?
|
| Sirolimus | 1 | 2013 | 118 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 3 | 2013 | 50 | 0.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2013 | 42 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 1341 | 0.110 |
Why?
|
| CD3 Complex | 1 | 2012 | 35 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2012 | 31 | 0.110 |
Why?
|
| Proanthocyanidins | 1 | 2012 | 4 | 0.110 |
Why?
|
| Catechin | 1 | 2012 | 26 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2015 | 753 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 778 | 0.100 |
Why?
|
| Retina | 1 | 2014 | 252 | 0.100 |
Why?
|
| Stilbenes | 1 | 2012 | 57 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 384 | 0.100 |
Why?
|
| Aged | 5 | 2021 | 14842 | 0.100 |
Why?
|
| Ultraviolet Rays | 1 | 2012 | 130 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 250 | 0.100 |
Why?
|
| Oxidants | 1 | 2011 | 48 | 0.100 |
Why?
|
| Reactive Nitrogen Species | 1 | 2011 | 32 | 0.100 |
Why?
|
| Cytokines | 3 | 2018 | 866 | 0.100 |
Why?
|
| Middle Aged | 6 | 2021 | 21119 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 306 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 1293 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2018 | 7028 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2012 | 122 | 0.100 |
Why?
|
| Genetic Therapy | 1 | 2013 | 291 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 626 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 710 | 0.100 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 168 | 0.100 |
Why?
|
| Electroretinography | 2 | 2020 | 122 | 0.090 |
Why?
|
| Genetic Vectors | 3 | 2008 | 311 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 514 | 0.090 |
Why?
|
| Orthomyxoviridae | 1 | 2009 | 6 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 1753 | 0.090 |
Why?
|
| Metalloporphyrins | 1 | 2009 | 25 | 0.090 |
Why?
|
| Acetylation | 2 | 2020 | 94 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2014 | 902 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2012 | 272 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1070 | 0.090 |
Why?
|
| Immunization | 1 | 2009 | 86 | 0.090 |
Why?
|
| Nitric Oxide | 1 | 2011 | 382 | 0.090 |
Why?
|
| Free Radical Scavengers | 1 | 2009 | 112 | 0.080 |
Why?
|
| Transgenes | 3 | 2015 | 92 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 4843 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 24 | 0.080 |
Why?
|
| Diet | 1 | 2012 | 513 | 0.080 |
Why?
|
| MART-1 Antigen | 2 | 2004 | 10 | 0.080 |
Why?
|
| Adenoviridae | 2 | 2004 | 295 | 0.080 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2006 | 10 | 0.070 |
Why?
|
| Glycolysis | 2 | 2018 | 79 | 0.070 |
Why?
|
| Influenza A virus | 1 | 2006 | 13 | 0.070 |
Why?
|
| Lymphocyte Depletion | 2 | 2018 | 34 | 0.070 |
Why?
|
| Autoantigens | 2 | 2006 | 91 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 434 | 0.070 |
Why?
|
| Self Tolerance | 1 | 2006 | 8 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2006 | 42 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 420 | 0.070 |
Why?
|
| Immunodominant Epitopes | 1 | 2004 | 13 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 938 | 0.060 |
Why?
|
| Viral Structural Proteins | 1 | 2004 | 10 | 0.060 |
Why?
|
| Cross-Priming | 1 | 2004 | 10 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2004 | 110 | 0.060 |
Why?
|
| Interleukin-17 | 2 | 2015 | 62 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2004 | 483 | 0.060 |
Why?
|
| Protein Transport | 1 | 2004 | 280 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 1172 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 852 | 0.060 |
Why?
|
| Acetyl Coenzyme A | 1 | 2022 | 10 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 138 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2022 | 46 | 0.050 |
Why?
|
| Cell Line | 2 | 2018 | 1752 | 0.050 |
Why?
|
| Rats | 2 | 2020 | 5300 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2022 | 117 | 0.050 |
Why?
|
| Oncogenes | 1 | 2022 | 71 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 659 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 20 | 0.050 |
Why?
|
| Rats, Inbred BN | 1 | 2020 | 51 | 0.050 |
Why?
|
| Disease | 1 | 2020 | 41 | 0.050 |
Why?
|
| Receptors, Interferon | 1 | 2020 | 8 | 0.050 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2020 | 15 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2020 | 17 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 215 | 0.050 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 21 | 0.050 |
Why?
|
| Intraocular Pressure | 1 | 2020 | 143 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2020 | 97 | 0.050 |
Why?
|
| Cadaver | 1 | 2020 | 136 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 475 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2020 | 46 | 0.050 |
Why?
|
| Unfolded Protein Response | 1 | 2020 | 70 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2020 | 202 | 0.040 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2019 | 6 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 948 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2019 | 294 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 80 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 110 | 0.040 |
Why?
|
| Carbazoles | 1 | 2018 | 46 | 0.040 |
Why?
|
| Warm Ischemia | 1 | 2018 | 8 | 0.040 |
Why?
|
| Cold Ischemia | 1 | 2018 | 5 | 0.040 |
Why?
|
| Transplantation Tolerance | 1 | 2018 | 13 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2018 | 31 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 35 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2018 | 25 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2021 | 458 | 0.040 |
Why?
|
| Adolescent | 2 | 2021 | 8903 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1663 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 200 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 21375 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2018 | 121 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 714 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2019 | 195 | 0.040 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 59 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2018 | 308 | 0.040 |
Why?
|
| Receptors, CCR4 | 1 | 2016 | 2 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 260 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 244 | 0.040 |
Why?
|
| Phosphofructokinase-2 | 1 | 2016 | 4 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2016 | 15 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 63 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 56 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 190 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2016 | 305 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 8 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 648 | 0.030 |
Why?
|
| Biolistics | 1 | 2015 | 5 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 19 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 118 | 0.030 |
Why?
|
| Proteomics | 1 | 2017 | 246 | 0.030 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2014 | 5 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 337 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 498 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1194 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 2014 | 39 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2356 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 901 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 301 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 196 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 729 | 0.030 |
Why?
|
| South Carolina | 1 | 2020 | 2750 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 1199 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 326 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2015 | 523 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 770 | 0.030 |
Why?
|
| DNA | 1 | 2015 | 597 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 138 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 182 | 0.020 |
Why?
|
| Transfection | 1 | 2013 | 782 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 562 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 5708 | 0.020 |
Why?
|
| Forecasting | 1 | 2009 | 277 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 369 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 799 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2006 | 59 | 0.020 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2004 | 3 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2004 | 8 | 0.020 |
Why?
|
| Simplexvirus | 1 | 2004 | 26 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 765 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 2093 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 282 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 2004 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 376 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1548 | 0.010 |
Why?
|